Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 1.00 |
| ▸ | SLC9A3 | P48764 | 1/20 | 1.00 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eniporide SCHEMBL6619624 | 1.00 | SLC9A1 (1.00) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL29359767 | 0.97 | SLC9A1 (0.95) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL8444822 | 0.89 | SLC9A1 (0.80) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL6623631 | 0.85 | SLC9A1 (0.73) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL8032919 | 0.85 | SLC9A1 (0.72) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL8444794 | 0.84 | SLC9A1 (0.73) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL8444811 | 0.84 | SLC9A1 (0.72) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL13602342 | 0.84 | SLC9A1 (0.71) | SLC9A1SLC9A3SLC9A2 | |
| Hydrochloric Acid SCHEMBL8705699 | 0.83 | SLC9A1 (0.71) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL8447087 | 0.83 | SLC9A1 (0.71) | SLC9A1SLC9A3SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| US-20240041804-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | FONDATION ESPERARE (CH) | 2024-02-08 | — | — | US | claimed |
| US-20240033284-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2024-02-01 | — | — | US | claimed |
| EP-4203930-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Fondation EspeRare (CH) | 2023-07-05 | — | — | EP | claimed |
| WO-2022043343-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | FONDATION ESPERARE (CH) | 2022-03-03 | — | — | WO | claimed |
| EP-3960165-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Fondation EspeRare (CH) | 2022-03-02 | — | — | EP | claimed |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | UNIV MINNESOTA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260021169-A1 | CO-TRANSPLANTATION OF MMP-9 ENHANCED MESENCHYMAL STEM CELLS AND PANCREATIC ISLETS FOR THE TREATMENT OF DIABETES | UNIV MARYLAND (US) | 2026-01-22 | — | — | US | disclosed |
| US-12527729-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12529033-B2 | Method of isolating myogenic progenitors using CD54 | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20220062329-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2022043343-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | FONDATION ESPERARE (CH) | 2022-03-03 | — | — | WO | disclosed |
| EP-3960165-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Fondation EspeRare (CH) | 2022-03-02 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220047624-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220040225-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220023336-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021169-A1 | CO-TRANSPLANTATION OF MMP-9 ENHANCED MESENCHYMAL STEM CELLS AND PANCREATIC ISLETS FOR THE TREATMENT OF DIABETES | MMP9, MMP1, IAPP | SLC9A1 81/4885SLC9A3 188/4885SLC9A2 264/4885 |
| US-20240041804-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | NHERF1, SLC9A1, SLC9A2 | SLC9A1 2/4885SLC9A3 5/4885SLC9A2 3/4885 |
| US-12527729-B2 | Minoxidil adjuvant therapies | RXRA, RXRB, RXRG | SLC9A1 236/4885SLC9A3 287/4885SLC9A2 143/4885 |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | FGFR2, FGF2, FGF1 | SLC9A1 2648/4885SLC9A3 1217/4885SLC9A2 1596/4885 |
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | SLC9A1 357/4885SLC9A3 428/4885SLC9A2 278/4885 |
| US-12529033-B2 | Method of isolating myogenic progenitors using CD54 | PAXBP1, PAX3, PAX8 | SLC9A1 3327/4885SLC9A3 2567/4885SLC9A2 3109/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | SLC9A1 10/4885SLC9A3 4/4885SLC9A2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.